{"ticker": {"uuid": "c9d94ab1-6d4f-45b5-b978-7ca76e02964a", "symbol": "TYRA", "name": "Tyra Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to earnings forward of Tyra Biosciences, Inc. \u2013 NASDAQ:TYRA", "summary": "This page from TradingView displays financial information for Tyra Biosciences, Inc. (NASDAQ:TYRA), specifically focusing on its price-to-earnings forward metric. The content indicates that market data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.", "url": "https://www.tradingview.com/symbols/NASDAQ-TYRA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T11:12:08", "published_display": "11 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of TYRA and Institutional Flows", "summary": "This article analyzes the behavioral patterns and institutional flows for Tyra Biosciences Inc. (NASDAQ: TYRA) using AI models. It identifies strong sentiment across all time horizons, supporting an overweight bias, and provides specific position trading, momentum breakout, and r", "url": "https://news.stocktradersdaily.com/news_release/98/Behavioral_Patterns_of_TYRA_and_Institutional_Flows_071026115201_1783698721.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T12:10:43", "published_display": "10 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tyra Biosciences, Inc. \u2013 BOATS:TYRA", "summary": "The article discusses the \"Price to sales forward\" metric for Tyra Biosciences, Inc. (TYRA) on the TradingView platform. It provides financial data for the company, indicating the period, value, and change percentages for this metric. The page appears to be a financial data prese", "url": "https://www.tradingview.com/symbols/BOATS-TYRA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T10:10:17", "published_display": "09 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Tyra Biosciences, Inc. \u2013 BOATS:TYRA", "summary": "This article provides financial information for Tyra Biosciences, Inc. (TYRA) on the Blue Ocean Alternative Trade System (BOATS) via TradingView. It specifically highlights the company's enterprise value to EBIT forward data. The content appears to be a financial snapshot from a ", "url": "https://www.tradingview.com/symbols/BOATS-TYRA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T04:39:27", "published_display": "09 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation", "summary": "Wolfe Research has initiated coverage of Tyra Biosciences (TYRA) with a \"peer perform\" recommendation. This suggests that Wolfe Research expects Tyra Biosciences to perform in line with its industry peers.", "url": "http://www.msn.com/en-us/money/topstocks/wolfe-research-initiates-coverage-of-tyra-biosciences-tyra-with-peer-perform-recommendation/ar-AA23Cf0n?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-08T13:39:27", "published_display": "08 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Tyra Biosciences, Inc. \u2013 NASDAQ:TYRA", "summary": "The article provides a title referencing the enterprise value to EBITDA forward for Tyra Biosciences, Inc. (NASDAQ: TYRA). It appears to be a stub or a section from a financial data platform like TradingView, offering navigation to financial data, news, and community features rel", "url": "https://www.tradingview.com/symbols/NASDAQ-TYRA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T04:42:06", "published_display": "07 Jul 2026 04:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?", "summary": "Tyra Biosciences, Inc. (TYRA) is positioned as a promising biotech stock due to upcoming clinical milestones, particularly the anticipated complete response data from its SURF302 study in August 2026. Oppenheimer initiated coverage with an \"Outperform\" rating and a $50 price targ", "url": "https://www.insidermonkey.com/blog/is-tyra-biosciences-inc-tyra-stock-a-biotech-opportunity-ahead-of-key-surf302-trial-data-1792077/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-30T13:09:11", "published_display": "30 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2500 Growth Benchmark", "summary": "Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been added to the Russell 2500 Growth Benchmark, as well as the Russell 2000 Growth Benchmark and Russell 3000E Growth Benchmark. Concurrently, the company was dropped from several other Russell benchmarks, including the Russell Small C", "url": "https://www.marketscreener.com/news/tyra-biosciences-inc-nasdaqgs-tyra-added-to-russell-2500-growth-benchmark-ce7f5fdfdd88f621", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:40:50", "published_display": "29 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Growth Benchmark", "summary": "Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been added to the Russell 2000 Growth Benchmark. This news comes alongside other recent index adjustments, including being dropped from several Russell Value and Microcap indices, but added to the Russell 3000E Growth Benchmark. The com", "url": "https://www.marketscreener.com/news/tyra-biosciences-inc-nasdaqgs-tyra-added-to-russell-2000-growth-benchmark-ce7f5fded18bf524", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:40:06", "published_display": "29 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(TYRA) Movement Within Algorithmic Entry Frameworks", "summary": "The article provides an algorithmic analysis of Tyra Biosciences Inc. (NASDAQ: TYRA), indicating strong sentiment across all time horizons supporting an overweight bias. It outlines detailed institutional trading strategies, including position trading, momentum breakout, and risk", "url": "https://news.stocktradersdaily.com/news_release/132/TYRA_Movement_Within_Algorithmic_Entry_Frameworks_062926104401_1782744241.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-29T10:40:50", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell Microcap Index", "summary": "Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been removed from the Russell Microcap Index. This follows earlier reports of its exclusion from the Russell 3000 Value Benchmark and the Russell 2500 Value Benchmark. The company, a clinical-stage biotechnology firm, focuses on develop", "url": "https://www.marketscreener.com/news/tyra-biosciences-inc-nasdaqgs-tyra-dropped-from-russell-microcap-index-ce7f5fdedd88f621", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:48:38", "published_display": "29 Jun 2026 05:48", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Most Promising Cancer Stocks According to Wall Street Analysts", "summary": "This article identifies Tyra Biosciences, Inc. (NASDAQ:TYRA) as one of the most promising cancer stocks, citing an Outperform rating and $50 price target from Oppenheimer. The firm's confidence is based on upcoming clinical milestones, particularly full response data from the SUR", "url": "https://www.insidermonkey.com/blog/10-most-promising-cancer-stocks-according-to-wall-street-analysts-1790154/3/", "source_name": "Insider Monkey", "published_at": "2026-06-28T18:40:06", "published_display": "28 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 | TYRA BIOSCIENCES, INC.(TYRA.US) Insider Proposes to Sell 9.54 Million in Common Stocks", "summary": "An insider at TYRA BIOSCIENCES, INC. (TYRA.US) has filed a Form 144 proposing to sell common stocks valued at $9.54 million. The filing indicates a significant potential transaction by an insider of the company.", "url": "https://www.moomoo.com/news/flash/22709456/form-144-tyra-biosciences-inc-tyraus-insider-proposes-to-sell", "source_name": "Moomoo", "published_at": "2026-06-27T19:41:28", "published_display": "27 Jun 2026 19:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 TYRA BIOSCIENCES For: 26 June By Investing.com", "summary": "This article announces that TYRA Biosciences has filed a Form 144 for June 26. A Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article provides only this brief detail and is published by Investing.com.", "url": "https://ca.investing.com/news/stock-market-news/form-144-tyra-biosciences-for-26-june-93CH-4710229", "source_name": "Investing.com Canada", "published_at": "2026-06-26T22:09:54", "published_display": "26 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TYRA (NASDAQ: TYRA) sells common shares under Rule 144 in June 2026", "summary": "NEXTECH VI ONCOLOGY SCSP reported four sales of TYRA (NASDAQ: TYRA) common stock in June 2026 under a Rule 144 notice, with transactions occurring on June 1, 23, 24, and 25. The sales were handled by Merrill Lynch, generating total proceeds exceeding $4 million. The filing provid", "url": "https://www.stocktitan.net/sec-filings/TYRA/144-tyra-biosciences-inc-sec-filing-036782103ab5.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:09:54", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Bioscience, Inc Actuals & Estimates (NASDAQ:TYRA)", "summary": "This article provides an overview of Tyra Biosciences, Inc. (NASDAQ:TYRA) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, earnings per share, revenue, and market capitalization. The company's upcoming ", "url": "https://www.tradingview.com/symbols/NASDAQ-TYRA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:09:54", "published_display": "26 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TYRA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Tyra Biosciences, Inc. (TYRA) stock, including analyst ratings, historical performance, and future earning estimates. It details the company's financial status, market capitalization, and upcoming earnings report. The piece al", "url": "https://www.tradingview.com/symbols/NASDAQ-TYRA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:40:37", "published_display": "26 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences (TYRA) Gains Attention On Phase II Results, Is The Upside Already Priced In?", "summary": "Tyra Biosciences (TYRA) has gained attention due to recent positive Phase II results for its experimental therapy Dabogratinib, used for non-muscle invasive bladder cancer. While short-term stock momentum has cooled, long-term investors have seen significant gains. The article di", "url": "https://www.sahmcapital.com/news/content/tyra-biosciences-tyra-gains-attention-on-phase-ii-results-is-the-upside-already-priced-in-2026-06-25", "source_name": "Sahm", "published_at": "2026-06-26T05:41:30", "published_display": "26 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Tyra Biosciences Inc (TYRA), focusing on support, resistance, indicators, and moving averages. It details various technical indicators like MACD, RSI, KDJ, and ATR, along with their values and directional signals. The analysis conclud", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tyra/technical", "source_name": "TradingKey", "published_at": "2026-06-23T03:40:32", "published_display": "23 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50", "summary": "Oppenheimer has reiterated its Buy rating on TYRA BIOSCIENCES, INC. (TYRA.US) and maintained its price target at $50. This continued endorsement by the firm suggests a positive outlook on the company's future performance and valuation. Investors may use this information as part o", "url": "https://news.futunn.com/en/post/74731463/oppenheimer-maintains-tyra-biosciences-inc-tyraus-with-buy-rating-maintains", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-19T19:10:30", "published_display": "19 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Tyra Biosciences Inc (TYRA), listing its major shareholders by proportion as well as a breakdown of shareholder types, including venture capital, hedge funds, and individual investors. It also provides institutional shareholding d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tyra/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:01", "published_display": "18 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Tyra Biosciences Inc (TYRA) regarding its dividend history and stock splits. It states that no dividends have been distributed over the past five years and no stock split data is available. The article serves as a record of financial events fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tyra/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T04:39:01", "published_display": "18 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Tyra Biosciences Inc (TYRA), detailing analyst ratings, price targets, and EPS estimates. Based on 15 analysts, the stock has a \"Buy\" consensus rating with a target price of USD 31.00, suggesting an 81.75% upside. The company's previ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tyra/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T15:09:55", "published_display": "17 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TYRA Initiated Coverage by Jones Trading -- Rating Set to Buy", "summary": "Jones Trading initiated coverage on Tyra Biosciences (TYRA) with a Buy rating and a $56.00 price target. This positive outlook is supported by endorsements from other analysts, although the company's GF Score\u2122 of 30 and recent insider selling activity suggest potential risks that", "url": "https://www.gurufocus.com/news/8920903/tyra-initiated-coverage-by-jones-trading-rating-set-to-buy", "source_name": "GuruFocus", "published_at": "2026-06-17T15:09:55", "published_display": "17 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Inc (TYRA) Institutional Confidence", "summary": "This article from TradingKey provides an overview of institutional confidence in Tyra Biosciences Inc (TYRA). It lists the institutional shareholders and their shareholdings, highlighting changes in their positions. The primary focus is on the \"Institutional Shareholding\" and \"Sh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tyra/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T14:09:55", "published_display": "17 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQOVl2X0ZTNUhueVVjalZvUG04Y3FTQ2gtdDhVem1mSzJaN1ZRVjlnVnF1aElqZWl5X2E2SE83SGhlS3FUUmQtNHBkaXQwZzkzM3RHVHhCem54b0lwV0s2aWFBZmVyMEdHYXNMcjhZNm5kbmlnTTFRQ2FKTlFzUDFRT2RQQU1lOFVRaWlJck9KX05nMFZRQ1Y4MENVRGg1WF9PQ2d4cA?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says", "summary": "BofA Securities reiterated its Underperform rating and $3 price target for Tyra Biosciences, noting weak investor sentiment due to macro pressures and renewed concerns about the SURF-302 program's competitive landscape. The analyst highlights that despite the unmet need in HR+ /H", "url": "https://www.moomoo.com/news/post/71340510/tyra-biosciences-weak-investor-sentiment-reflects-macro-pressures-renewed-surf", "source_name": "Moomoo", "published_at": "2026-06-10T22:39:53", "published_display": "10 Jun 2026 22:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Urothelial Carcinoma Market on Track for Major Expansion by 2036, According to DelveInsight | Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Infinity", "summary": "The Urothelial Carcinoma market is projected for significant expansion by 2036, driven by an increasing incidence of bladder cancer, advancements in immunotherapies and targeted therapies, and a strong pipeline of novel drugs. Key players like Bristol-Myers Squibb, Astellas Pharm", "url": "https://www.barchart.com/story/news/2406922/urothelial-carcinoma-market-on-track-for-major-expansion-by-2036-according-to-delveinsight-bristol-myers-squibb-astellas-pharma-pfizer-johnson-johnson-pfizer-tyra-biosciences-infinity", "source_name": "Barchart", "published_at": "2026-06-10T19:10:07", "published_display": "10 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42", "summary": "BofA Securities has reiterated its Buy rating for TYRA Biosciences, Inc. (TYRA.US) and increased the price target to $42. This sustained positive outlook from the financial firm indicates confidence in the company's future performance. The raised target price suggests an expectat", "url": "https://www.moomoo.com/news/post/71330048/bofa-securities-maintains-tyra-biosciences-inc-tyraus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-06-10T17:39:04", "published_display": "10 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59", "summary": "Barclays analyst Eliana Merle has reiterated a Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US) and maintained a target price of $59. According to TipRanks, Merle has a 36.8% success rate and a 1.4% average return over the past year. This rating indicates a continued positive outl", "url": "https://www.moomoo.com/news/post/71061966/barclays-maintains-tyra-biosciences-inc-tyraus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-08T12:10:04", "published_display": "08 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences (NASDAQ: TYRA) details 2026 shareholder meeting voting outcomes", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNMXdFb0dFOVJ1akxlaTZpT1NSN1NLbmVFNFZicUl1QW1LbXBwWVlqM194RTRLWEc1VTZxeW13TmxEUHo0UUp5dWowMzFhcG9waGliMS1vcGtscTVHb01nSkFOTVYzSU45bzYtbUdiWTBnZXpiUWxxbm9wVWIxSzM2YVlJU3QxNFAya1kyZExSVVhmSHJsSlFVMXMtcjd6em52U0FTaEN0ZFVsREtMVGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQemg1TnJqckVhT0NhWm5hSElpRmc1WUc0WlBxV2stVWp0aE5pTWNiaHdfYXRLbTRTWGwtMVVHLU1sU3NjaVk1ZFh5Umt5MmRyRVRRLXlKTUhFMTdYdnU2VWZiNmlMb2tCQjJEcFVqZ1A3ZXp4MWc3VlV2c1lhdkZPSzNWcjF6X3Z5TFBaekdEdmJVY2V6NUI3LWtUSndfNzQ4ZDQ1MGRkM0hwQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNUURGcFFlZVJNeWlOT0NDWFFITGtsNVJpZjRVUEFFRDVTV25qYUZKaEtZWmFoZWdTYXo1OEN1QXZrWHExTUpxZG5ib0NaQzBYWjcxalVPMERRNUlrZWVkeGtjakRfVXRxZ0ExSGJMbnJLZ2ZYOGJFbnhEUmlHSW50TU5XLS1qOE12akpDQUtlX0t6UDRJYmxkOFNsN1pMMkw1eEpjeWpjX2hsV0ZHaS0yS2E0YTBBZGhfMVJXWFFra2czZHRnLUUyd3lxOGQ3R3JnZGp1a0I5bzBmYnlFb3h0dWgtVXE?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQSnZEMURCZUd0SkwwdEFpV0tRd3RmVjViMjZTVFgwT180WExadlFVeG9pQzZTU3EtaHAzYUZNcFJMaUgwUG16QUVBTHl3T0ZJSVB5dXlXOXJfZzA3ZUlSNTVyTjRveFN6MHozMC03a1VqNkVXc082RWtIS19SRFFrWEJGanlZM3ppQUNHNGNWWlJTRjVBem83UmJaTVhQQTQzMVE1RzY0STlOMEpMdEpNRlo5TWQzWU1ONUF5bXlLUGJKbXJqYXg0eW4yNkp0ajVYT1p5d29PMA?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Tyra Biosciences\u2019 (TYRA) Dabogratinib 3\u00d73 Focus Reframing Its Risk Reward Profile?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQUjMzMk55ckNKekxISUo2RThUTUJjRFBSc2VQSFpSVjg3ZUdfTExrWmdCZFJTZEFpMWtTYlc4TXV2OGlNMHRmcG44MFN3dlBCOHgxTXA4N1VkQlZNVmdIVGhVODRRazRITUxhZEUyNzVzSlBqOTlxT3ZDby1aU2NwN3lhbnFMcW1IOTZfNzBQN0VQc1VYaXFadkhkSk9tUEZCSmRVckstUkZHQnhvTjdRRXdTSTZ4eG94a3FsTmV1cnpobkROTDR1VzhJamw0eU9UTnFWWXAyblgwemZVWEpLU0V5VjLSAeoBQVVfeXFMTTQ0SGhmRjJoT1RLN3pvZ2VaaHE1dWlWeE9MZW42ZFl4Qk5TMFpYT0tjN29jb05tUURqUkY4TzRkdFVHaEFHNU9xWUFlaEYxX25ZcF9ad0NXVExtTU1uME10eTNFWkVhdGZ3NUFRUG0yU1ZsWHdTMVZ0Qng2NUQyUFRZR1p5cE9LTGlnUG0xak04R2FlZTJUOE92RTRGa2xVWEswUTJ1aWdidzRsN1Jhb1kxNVNsa2JqSFZGck1oZV9zdmFtQU9Xak5tejFmcFQ5YVlyaS1pN3RqRldMMEZQXzRVWFZOTzU0ZE5n?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcjA5WEZUcHNkOVhma0dyTTVkWlFfMTVzZUY3TzQ4d1VOb1RjWFRoWFJhV0x2N0NGMmt0OHVlaFN3a1lVa3JTOGlrNU1qU1ZPUFJhbWhobzFLYW9Jb3BFWWhLdzYzZU9YM1lQRkU4cTF4MXdfM05lUjE2VTVPOUNqbnMzZjl4WmhsUXZSeFAxQ1AyOEU1M1lxdE1hdXRJWEZvSlpnMjVaeC1Ldw?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tyra Biosciences Q1 Net Loss Widens", "summary": "", "url": "https://finance.yahoo.com/news/tyra-biosciences-q1-net-loss-123756978.html", "source_name": "MT Newswires", "published_at": "2026-05-13T12:37:56+00:00", "published_display": "13 May 2026 12:37", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOdWtYVWtYRUpocTZQUnJneFNFeHlmTzNGbzBCc3phZDFoSHJjQXN0R0RXem5iajEwT0VKclRWNGVTbWRsTk5QVWV0ZzNXSm05czNnX3pVb0FuMzJhQ1FsZDdXT3VUT3g4UWxlSGE2TXl2RlZEOUxfUGpWcFRQMGdBbEVub0hEWWFYRWk5bUp1QXB3b2xQbWF2VjEyTUpsbW5RTkNNYUp0RjFyT0locEluNjhaZWlmbHFiaW1FUWpfbjhEWkl6cVhaMlh5NDdyV1pXU3FLTW9n?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tyra Biosciences to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPaUVKSC1teUdwU0ZLa2oyVmpLei1rSmctOVFCRlpTVlZQNFZwMEFIUUZleHNiZE4yZW90UnYtbEdYMzFGdkZDSHBmTWZteHBKRDNidms0V3Z3WjJqcG1rNVc1dEYzUS1lMGpMSlBSalVjZXhVWHlaLWRvdl8zTGtVNkxzMk1XM1VuMmhMNUp1ZTNWYXVrVFVKR0tUUjduQVdwMmlsdTlVN1U2TV9zRWJLb1N6bERHUlRFR0YxRg?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three Tyra Biosciences investor events start May 13, with webcasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNXzBldW13V18zVDB4ZEEtbDFfMFFsXzBRVExtZlJxeURCXzhyVVdzLWVzYWNwTlZ4bWwyLTZPMktNMVV5RkRnanRoUUdSRkllU0xFUU00bWJBT3oySmFIM0pnelcwUGZWeks0eF9Wb0hCVTJZb0ZiVThPakhLckZkY25fVmdxTm9fdXBQWmk2TVR3NEJWa245WlVudElGYXF4blZma1BuMk9YeHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRzNFMWRodlNySVFpLVdLcTc1VkpZaXZ2STRHQXZFaXhRTjB3cGo0UFR2aklxandvdXhOdFFqTDNnX0VndENRTnFxVC1nRGF6MXJ0Wm0wYnJ4VU9hWHRmLWJKeFdCTHhFd2ozWEtlanVFSlJpRUxnV2dva2Ria01FUDZmenNNUzdkUjJHUGlCQVA4NGh2RVVfTnFsd0I5RjZIQy1YM2JjQUlLZEk?oc=5", "source_name": "Market source", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tyra Biosciences, Inc. ($TYRA) CEO 2025 Pay Revealed", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNS2poS3NPUFlHbHFpYkctTlotdk14NFFZek9pa0J1RDNXVEI0ZUw1M0VaTlBvQ2lvNTB0a2Vjb1U3cGhka2xTU01SZTB6RUhmQzRoa3BEWklhT1gtcVpKSXlqX09GNlR2SEJTWlkxVDZGR2phM0V0b1A0TWNMYzEtcmJTSmNnd2M3dkFEaXVmYjN0N3N1MHZGWg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPWnltWUlONW1qWjVjbHNRZUpNeUhISjY5ZzNSRlAtR0pqMnRadHFGdi1KdTcwYlo2YXo2a1czdG5uMHFINDVBb1NwTFlCTUIxX0UxcmtkQ3pJSVA3YUFkaFdkbldpMUczaUpsNkdpLWM2M2hXcFZ1ZDl4dXl1NFU1RWQtelJHcS1GeS1DQjhpTnA0ZUYyc2VhVmV4MTZZR2F2RFJ3?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Boone Capital Backs Tyra Biosciences As FGFR3 Trials Shape Outlook", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-21T07:00:00+00:00", "published_display": "21 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOdXI0MkxRb2otREhoTVowemozMWZ1dE53ZEwwVEFfYm1fNzRGazRKaXdtZmtZaFRHWnd3TGFoZFB0cUp6ejg3RTZJb3JQTTRrOWc1aVg0LWF6ZUc4SVdJZEVGR3c2UkpCc1JWTUEzTG9UaVlwM1Fmalc1a1NkeU1lMURDYzdkR2NlWmpwei1R?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences price target raised to $53 from $37 at Wedbush", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPWGdkTENxTmVHV3RiMGVzZHpnT2pMNkNVdGpVYTFtQXpRM1ZXaEVYMWRBeElEeC1HeENwdDlRR2txT0JoeHQxbmNSNGdhb1MyekE2cDFaVFZITHJXWGY1dFBQbWJuWWh0NEs4RVVDSGhHR0R0RFVzU3p2LXc3bk5hNEt0MjJKTUM4TEE?oc=5", "source_name": "Market source", "published_at": "2026-02-14T08:00:00+00:00", "published_display": "14 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences (TYRA) Stock Forecast and Price Target 2026 $TYRA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1mbGwwSWUwdXIxSTRZLVFXSnhaS3lsMDVFUjRSWEpZODl5ZDBtRTJJSzE0Q2FUUkJSa0tIeHRoZUlrRXFKRUZmbHE1UmNGWk9Mbk1pTzlfZUVZbFViX1dCN05kRjRHdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:41:20+00:00", "published_display": "11 May 2024 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNVmJiYVVERjVFcktQdTlyMURicjJRbGdUbWYzYTBGZmJsTkhYWjUzdmg5ZE9ESUFTazVaNW0tcTB1eG9jalNnaHNQRy1xWWI4OThQVlZ1eWV2QjBoMEljdFl6ZnVKV2ZwZTFuYnVOVW85d2FJTkl1N2tSSlhBTm0wdFdCcGw5T1gwbFo2UkV6dGhGTU1ZNEFHcHFHR204RkhnRThoY1l1Mkt1WXJvX1c5VktMa2lpbVZ4cWRWMUJJb05VNVYz?oc=5", "source_name": "PR Newswire", "published_at": "2024-02-02T08:00:00+00:00", "published_display": "02 Feb 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences (TYRA) Stock Price, News & Analysis $TYRA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9ZMTd6OEFxbXBTb2hBcEN6b3BwOFlQN0lzX3dlczgydDZreVRFVjhJTkdFWUFKWWNfNS1ka0VieFNFOTgzWDZvVnJaQWdIMmxPTkxNdXpsb3dKdw?oc=5", "source_name": "MarketBeat", "published_at": "2021-09-17T02:41:54+00:00", "published_display": "17 Sep 2021 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TYRA Stock Price and Chart \u2014 NASDAQ:TYRA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1IWE5kRjBXaldKc0paMWdaSHJuQ0NVaW93MXM5SDAtdDJRNnFWSTRmckpiY2V4NXpOVHU0cVNJUmQ3c3g3b2IwNGNHZnR5SHhrTVVpM01SVHAxbFlF?oc=5", "source_name": "TradingView", "published_at": "2021-09-14T06:44:46+00:00", "published_display": "14 Sep 2021 06:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to earnings forward of Tyra Biosciences, Inc. \u2013 NASDAQ:TYRA", "summary": "This page from TradingView displays financial information for Tyra Biosciences, Inc. (NASDAQ:TYRA), specifically focusing on its price-to-earnings forward metric. The content indicates that market data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.", "url": "https://www.tradingview.com/symbols/NASDAQ-TYRA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T11:12:08", "published_display": "11 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of TYRA and Institutional Flows", "summary": "This article analyzes the behavioral patterns and institutional flows for Tyra Biosciences Inc. (NASDAQ: TYRA) using AI models. It identifies strong sentiment across all time horizons, supporting an overweight bias, and provides specific position trading, momentum breakout, and r", "url": "https://news.stocktradersdaily.com/news_release/98/Behavioral_Patterns_of_TYRA_and_Institutional_Flows_071026115201_1783698721.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T12:10:43", "published_display": "10 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tyra Biosciences, Inc. \u2013 BOATS:TYRA", "summary": "The article discusses the \"Price to sales forward\" metric for Tyra Biosciences, Inc. (TYRA) on the TradingView platform. It provides financial data for the company, indicating the period, value, and change percentages for this metric. The page appears to be a financial data prese", "url": "https://www.tradingview.com/symbols/BOATS-TYRA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T10:10:17", "published_display": "09 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Tyra Biosciences, Inc. \u2013 BOATS:TYRA", "summary": "This article provides financial information for Tyra Biosciences, Inc. (TYRA) on the Blue Ocean Alternative Trade System (BOATS) via TradingView. It specifically highlights the company's enterprise value to EBIT forward data. The content appears to be a financial snapshot from a ", "url": "https://www.tradingview.com/symbols/BOATS-TYRA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T04:39:27", "published_display": "09 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation", "summary": "Wolfe Research has initiated coverage of Tyra Biosciences (TYRA) with a \"peer perform\" recommendation. This suggests that Wolfe Research expects Tyra Biosciences to perform in line with its industry peers.", "url": "http://www.msn.com/en-us/money/topstocks/wolfe-research-initiates-coverage-of-tyra-biosciences-tyra-with-peer-perform-recommendation/ar-AA23Cf0n?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-08T13:39:27", "published_display": "08 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Tyra Biosciences, Inc. \u2013 NASDAQ:TYRA", "summary": "The article provides a title referencing the enterprise value to EBITDA forward for Tyra Biosciences, Inc. (NASDAQ: TYRA). It appears to be a stub or a section from a financial data platform like TradingView, offering navigation to financial data, news, and community features rel", "url": "https://www.tradingview.com/symbols/NASDAQ-TYRA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T04:42:06", "published_display": "07 Jul 2026 04:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?", "summary": "Tyra Biosciences, Inc. (TYRA) is positioned as a promising biotech stock due to upcoming clinical milestones, particularly the anticipated complete response data from its SURF302 study in August 2026. Oppenheimer initiated coverage with an \"Outperform\" rating and a $50 price targ", "url": "https://www.insidermonkey.com/blog/is-tyra-biosciences-inc-tyra-stock-a-biotech-opportunity-ahead-of-key-surf302-trial-data-1792077/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-30T13:09:11", "published_display": "30 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2500 Growth Benchmark", "summary": "Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been added to the Russell 2500 Growth Benchmark, as well as the Russell 2000 Growth Benchmark and Russell 3000E Growth Benchmark. Concurrently, the company was dropped from several other Russell benchmarks, including the Russell Small C", "url": "https://www.marketscreener.com/news/tyra-biosciences-inc-nasdaqgs-tyra-added-to-russell-2500-growth-benchmark-ce7f5fdfdd88f621", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:40:50", "published_display": "29 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Growth Benchmark", "summary": "Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been added to the Russell 2000 Growth Benchmark. This news comes alongside other recent index adjustments, including being dropped from several Russell Value and Microcap indices, but added to the Russell 3000E Growth Benchmark. The com", "url": "https://www.marketscreener.com/news/tyra-biosciences-inc-nasdaqgs-tyra-added-to-russell-2000-growth-benchmark-ce7f5fded18bf524", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:40:06", "published_display": "29 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(TYRA) Movement Within Algorithmic Entry Frameworks", "summary": "The article provides an algorithmic analysis of Tyra Biosciences Inc. (NASDAQ: TYRA), indicating strong sentiment across all time horizons supporting an overweight bias. It outlines detailed institutional trading strategies, including position trading, momentum breakout, and risk", "url": "https://news.stocktradersdaily.com/news_release/132/TYRA_Movement_Within_Algorithmic_Entry_Frameworks_062926104401_1782744241.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-29T10:40:50", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell Microcap Index", "summary": "Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been removed from the Russell Microcap Index. This follows earlier reports of its exclusion from the Russell 3000 Value Benchmark and the Russell 2500 Value Benchmark. The company, a clinical-stage biotechnology firm, focuses on develop", "url": "https://www.marketscreener.com/news/tyra-biosciences-inc-nasdaqgs-tyra-dropped-from-russell-microcap-index-ce7f5fdedd88f621", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:48:38", "published_display": "29 Jun 2026 05:48", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Most Promising Cancer Stocks According to Wall Street Analysts", "summary": "This article identifies Tyra Biosciences, Inc. (NASDAQ:TYRA) as one of the most promising cancer stocks, citing an Outperform rating and $50 price target from Oppenheimer. The firm's confidence is based on upcoming clinical milestones, particularly full response data from the SUR", "url": "https://www.insidermonkey.com/blog/10-most-promising-cancer-stocks-according-to-wall-street-analysts-1790154/3/", "source_name": "Insider Monkey", "published_at": "2026-06-28T18:40:06", "published_display": "28 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 | TYRA BIOSCIENCES, INC.(TYRA.US) Insider Proposes to Sell 9.54 Million in Common Stocks", "summary": "An insider at TYRA BIOSCIENCES, INC. (TYRA.US) has filed a Form 144 proposing to sell common stocks valued at $9.54 million. The filing indicates a significant potential transaction by an insider of the company.", "url": "https://www.moomoo.com/news/flash/22709456/form-144-tyra-biosciences-inc-tyraus-insider-proposes-to-sell", "source_name": "Moomoo", "published_at": "2026-06-27T19:41:28", "published_display": "27 Jun 2026 19:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 TYRA BIOSCIENCES For: 26 June By Investing.com", "summary": "This article announces that TYRA Biosciences has filed a Form 144 for June 26. A Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article provides only this brief detail and is published by Investing.com.", "url": "https://ca.investing.com/news/stock-market-news/form-144-tyra-biosciences-for-26-june-93CH-4710229", "source_name": "Investing.com Canada", "published_at": "2026-06-26T22:09:54", "published_display": "26 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TYRA (NASDAQ: TYRA) sells common shares under Rule 144 in June 2026", "summary": "NEXTECH VI ONCOLOGY SCSP reported four sales of TYRA (NASDAQ: TYRA) common stock in June 2026 under a Rule 144 notice, with transactions occurring on June 1, 23, 24, and 25. The sales were handled by Merrill Lynch, generating total proceeds exceeding $4 million. The filing provid", "url": "https://www.stocktitan.net/sec-filings/TYRA/144-tyra-biosciences-inc-sec-filing-036782103ab5.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:09:54", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Bioscience, Inc Actuals & Estimates (NASDAQ:TYRA)", "summary": "This article provides an overview of Tyra Biosciences, Inc. (NASDAQ:TYRA) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, earnings per share, revenue, and market capitalization. The company's upcoming ", "url": "https://www.tradingview.com/symbols/NASDAQ-TYRA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:09:54", "published_display": "26 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TYRA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Tyra Biosciences, Inc. (TYRA) stock, including analyst ratings, historical performance, and future earning estimates. It details the company's financial status, market capitalization, and upcoming earnings report. The piece al", "url": "https://www.tradingview.com/symbols/NASDAQ-TYRA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:40:37", "published_display": "26 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences (TYRA) Gains Attention On Phase II Results, Is The Upside Already Priced In?", "summary": "Tyra Biosciences (TYRA) has gained attention due to recent positive Phase II results for its experimental therapy Dabogratinib, used for non-muscle invasive bladder cancer. While short-term stock momentum has cooled, long-term investors have seen significant gains. The article di", "url": "https://www.sahmcapital.com/news/content/tyra-biosciences-tyra-gains-attention-on-phase-ii-results-is-the-upside-already-priced-in-2026-06-25", "source_name": "Sahm", "published_at": "2026-06-26T05:41:30", "published_display": "26 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Tyra Biosciences Inc (TYRA), focusing on support, resistance, indicators, and moving averages. It details various technical indicators like MACD, RSI, KDJ, and ATR, along with their values and directional signals. The analysis conclud", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tyra/technical", "source_name": "TradingKey", "published_at": "2026-06-23T03:40:32", "published_display": "23 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50", "summary": "Oppenheimer has reiterated its Buy rating on TYRA BIOSCIENCES, INC. (TYRA.US) and maintained its price target at $50. This continued endorsement by the firm suggests a positive outlook on the company's future performance and valuation. Investors may use this information as part o", "url": "https://news.futunn.com/en/post/74731463/oppenheimer-maintains-tyra-biosciences-inc-tyraus-with-buy-rating-maintains", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-19T19:10:30", "published_display": "19 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Tyra Biosciences Inc (TYRA), listing its major shareholders by proportion as well as a breakdown of shareholder types, including venture capital, hedge funds, and individual investors. It also provides institutional shareholding d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tyra/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:01", "published_display": "18 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Tyra Biosciences Inc (TYRA) regarding its dividend history and stock splits. It states that no dividends have been distributed over the past five years and no stock split data is available. The article serves as a record of financial events fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tyra/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T04:39:01", "published_display": "18 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Tyra Biosciences Inc (TYRA), detailing analyst ratings, price targets, and EPS estimates. Based on 15 analysts, the stock has a \"Buy\" consensus rating with a target price of USD 31.00, suggesting an 81.75% upside. The company's previ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tyra/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T15:09:55", "published_display": "17 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TYRA Initiated Coverage by Jones Trading -- Rating Set to Buy", "summary": "Jones Trading initiated coverage on Tyra Biosciences (TYRA) with a Buy rating and a $56.00 price target. This positive outlook is supported by endorsements from other analysts, although the company's GF Score\u2122 of 30 and recent insider selling activity suggest potential risks that", "url": "https://www.gurufocus.com/news/8920903/tyra-initiated-coverage-by-jones-trading-rating-set-to-buy", "source_name": "GuruFocus", "published_at": "2026-06-17T15:09:55", "published_display": "17 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Inc (TYRA) Institutional Confidence", "summary": "This article from TradingKey provides an overview of institutional confidence in Tyra Biosciences Inc (TYRA). It lists the institutional shareholders and their shareholdings, highlighting changes in their positions. The primary focus is on the \"Institutional Shareholding\" and \"Sh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tyra/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T14:09:55", "published_display": "17 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQOVl2X0ZTNUhueVVjalZvUG04Y3FTQ2gtdDhVem1mSzJaN1ZRVjlnVnF1aElqZWl5X2E2SE83SGhlS3FUUmQtNHBkaXQwZzkzM3RHVHhCem54b0lwV0s2aWFBZmVyMEdHYXNMcjhZNm5kbmlnTTFRQ2FKTlFzUDFRT2RQQU1lOFVRaWlJck9KX05nMFZRQ1Y4MENVRGg1WF9PQ2d4cA?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says", "summary": "BofA Securities reiterated its Underperform rating and $3 price target for Tyra Biosciences, noting weak investor sentiment due to macro pressures and renewed concerns about the SURF-302 program's competitive landscape. The analyst highlights that despite the unmet need in HR+ /H", "url": "https://www.moomoo.com/news/post/71340510/tyra-biosciences-weak-investor-sentiment-reflects-macro-pressures-renewed-surf", "source_name": "Moomoo", "published_at": "2026-06-10T22:39:53", "published_display": "10 Jun 2026 22:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Urothelial Carcinoma Market on Track for Major Expansion by 2036, According to DelveInsight | Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Infinity", "summary": "The Urothelial Carcinoma market is projected for significant expansion by 2036, driven by an increasing incidence of bladder cancer, advancements in immunotherapies and targeted therapies, and a strong pipeline of novel drugs. Key players like Bristol-Myers Squibb, Astellas Pharm", "url": "https://www.barchart.com/story/news/2406922/urothelial-carcinoma-market-on-track-for-major-expansion-by-2036-according-to-delveinsight-bristol-myers-squibb-astellas-pharma-pfizer-johnson-johnson-pfizer-tyra-biosciences-infinity", "source_name": "Barchart", "published_at": "2026-06-10T19:10:07", "published_display": "10 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42", "summary": "BofA Securities has reiterated its Buy rating for TYRA Biosciences, Inc. (TYRA.US) and increased the price target to $42. This sustained positive outlook from the financial firm indicates confidence in the company's future performance. The raised target price suggests an expectat", "url": "https://www.moomoo.com/news/post/71330048/bofa-securities-maintains-tyra-biosciences-inc-tyraus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-06-10T17:39:04", "published_display": "10 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59", "summary": "Barclays analyst Eliana Merle has reiterated a Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US) and maintained a target price of $59. According to TipRanks, Merle has a 36.8% success rate and a 1.4% average return over the past year. This rating indicates a continued positive outl", "url": "https://www.moomoo.com/news/post/71061966/barclays-maintains-tyra-biosciences-inc-tyraus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-08T12:10:04", "published_display": "08 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences (NASDAQ: TYRA) details 2026 shareholder meeting voting outcomes", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNMXdFb0dFOVJ1akxlaTZpT1NSN1NLbmVFNFZicUl1QW1LbXBwWVlqM194RTRLWEc1VTZxeW13TmxEUHo0UUp5dWowMzFhcG9waGliMS1vcGtscTVHb01nSkFOTVYzSU45bzYtbUdiWTBnZXpiUWxxbm9wVWIxSzM2YVlJU3QxNFAya1kyZExSVVhmSHJsSlFVMXMtcjd6em52U0FTaEN0ZFVsREtMVGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQemg1TnJqckVhT0NhWm5hSElpRmc1WUc0WlBxV2stVWp0aE5pTWNiaHdfYXRLbTRTWGwtMVVHLU1sU3NjaVk1ZFh5Umt5MmRyRVRRLXlKTUhFMTdYdnU2VWZiNmlMb2tCQjJEcFVqZ1A3ZXp4MWc3VlV2c1lhdkZPSzNWcjF6X3Z5TFBaekdEdmJVY2V6NUI3LWtUSndfNzQ4ZDQ1MGRkM0hwQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNUURGcFFlZVJNeWlOT0NDWFFITGtsNVJpZjRVUEFFRDVTV25qYUZKaEtZWmFoZWdTYXo1OEN1QXZrWHExTUpxZG5ib0NaQzBYWjcxalVPMERRNUlrZWVkeGtjakRfVXRxZ0ExSGJMbnJLZ2ZYOGJFbnhEUmlHSW50TU5XLS1qOE12akpDQUtlX0t6UDRJYmxkOFNsN1pMMkw1eEpjeWpjX2hsV0ZHaS0yS2E0YTBBZGhfMVJXWFFra2czZHRnLUUyd3lxOGQ3R3JnZGp1a0I5bzBmYnlFb3h0dWgtVXE?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQSnZEMURCZUd0SkwwdEFpV0tRd3RmVjViMjZTVFgwT180WExadlFVeG9pQzZTU3EtaHAzYUZNcFJMaUgwUG16QUVBTHl3T0ZJSVB5dXlXOXJfZzA3ZUlSNTVyTjRveFN6MHozMC03a1VqNkVXc082RWtIS19SRFFrWEJGanlZM3ppQUNHNGNWWlJTRjVBem83UmJaTVhQQTQzMVE1RzY0STlOMEpMdEpNRlo5TWQzWU1ONUF5bXlLUGJKbXJqYXg0eW4yNkp0ajVYT1p5d29PMA?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Tyra Biosciences\u2019 (TYRA) Dabogratinib 3\u00d73 Focus Reframing Its Risk Reward Profile?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcjA5WEZUcHNkOVhma0dyTTVkWlFfMTVzZUY3TzQ4d1VOb1RjWFRoWFJhV0x2N0NGMmt0OHVlaFN3a1lVa3JTOGlrNU1qU1ZPUFJhbWhobzFLYW9Jb3BFWWhLdzYzZU9YM1lQRkU4cTF4MXdfM05lUjE2VTVPOUNqbnMzZjl4WmhsUXZSeFAxQ1AyOEU1M1lxdE1hdXRJWEZvSlpnMjVaeC1Ldw?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Q1 Net Loss Widens", "summary": "", "url": "https://finance.yahoo.com/news/tyra-biosciences-q1-net-loss-123756978.html", "source_name": "MT Newswires", "published_at": "2026-05-13T12:37:56+00:00", "published_display": "13 May 2026 12:37", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOdWtYVWtYRUpocTZQUnJneFNFeHlmTzNGbzBCc3phZDFoSHJjQXN0R0RXem5iajEwT0VKclRWNGVTbWRsTk5QVWV0ZzNXSm05czNnX3pVb0FuMzJhQ1FsZDdXT3VUT3g4UWxlSGE2TXl2RlZEOUxfUGpWcFRQMGdBbEVub0hEWWFYRWk5bUp1QXB3b2xQbWF2VjEyTUpsbW5RTkNNYUp0RjFyT0locEluNjhaZWlmbHFiaW1FUWpfbjhEWkl6cVhaMlh5NDdyV1pXU3FLTW9n?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPaUVKSC1teUdwU0ZLa2oyVmpLei1rSmctOVFCRlpTVlZQNFZwMEFIUUZleHNiZE4yZW90UnYtbEdYMzFGdkZDSHBmTWZteHBKRDNidms0V3Z3WjJqcG1rNVc1dEYzUS1lMGpMSlBSalVjZXhVWHlaLWRvdl8zTGtVNkxzMk1XM1VuMmhMNUp1ZTNWYXVrVFVKR0tUUjduQVdwMmlsdTlVN1U2TV9zRWJLb1N6bERHUlRFR0YxRg?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three Tyra Biosciences investor events start May 13, with webcasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNXzBldW13V18zVDB4ZEEtbDFfMFFsXzBRVExtZlJxeURCXzhyVVdzLWVzYWNwTlZ4bWwyLTZPMktNMVV5RkRnanRoUUdSRkllU0xFUU00bWJBT3oySmFIM0pnelcwUGZWeks0eF9Wb0hCVTJZb0ZiVThPakhLckZkY25fVmdxTm9fdXBQWmk2TVR3NEJWa245WlVudElGYXF4blZma1BuMk9YeHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRzNFMWRodlNySVFpLVdLcTc1VkpZaXZ2STRHQXZFaXhRTjB3cGo0UFR2aklxandvdXhOdFFqTDNnX0VndENRTnFxVC1nRGF6MXJ0Wm0wYnJ4VU9hWHRmLWJKeFdCTHhFd2ozWEtlanVFSlJpRUxnV2dva2Ria01FUDZmenNNUzdkUjJHUGlCQVA4NGh2RVVfTnFsd0I5RjZIQy1YM2JjQUlLZEk?oc=5", "source_name": "Market source", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences, Inc. ($TYRA) CEO 2025 Pay Revealed", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNS2poS3NPUFlHbHFpYkctTlotdk14NFFZek9pa0J1RDNXVEI0ZUw1M0VaTlBvQ2lvNTB0a2Vjb1U3cGhka2xTU01SZTB6RUhmQzRoa3BEWklhT1gtcVpKSXlqX09GNlR2SEJTWlkxVDZGR2phM0V0b1A0TWNMYzEtcmJTSmNnd2M3dkFEaXVmYjN0N3N1MHZGWg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPWnltWUlONW1qWjVjbHNRZUpNeUhISjY5ZzNSRlAtR0pqMnRadHFGdi1KdTcwYlo2YXo2a1czdG5uMHFINDVBb1NwTFlCTUIxX0UxcmtkQ3pJSVA3YUFkaFdkbldpMUczaUpsNkdpLWM2M2hXcFZ1ZDl4dXl1NFU1RWQtelJHcS1GeS1DQjhpTnA0ZUYyc2VhVmV4MTZZR2F2RFJ3?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Boone Capital Backs Tyra Biosciences As FGFR3 Trials Shape Outlook", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-21T07:00:00+00:00", "published_display": "21 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOdXI0MkxRb2otREhoTVowemozMWZ1dE53ZEwwVEFfYm1fNzRGazRKaXdtZmtZaFRHWnd3TGFoZFB0cUp6ejg3RTZJb3JQTTRrOWc1aVg0LWF6ZUc4SVdJZEVGR3c2UkpCc1JWTUEzTG9UaVlwM1Fmalc1a1NkeU1lMURDYzdkR2NlWmpwei1R?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences price target raised to $53 from $37 at Wedbush", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPWGdkTENxTmVHV3RiMGVzZHpnT2pMNkNVdGpVYTFtQXpRM1ZXaEVYMWRBeElEeC1HeENwdDlRR2txT0JoeHQxbmNSNGdhb1MyekE2cDFaVFZITHJXWGY1dFBQbWJuWWh0NEs4RVVDSGhHR0R0RFVzU3p2LXc3bk5hNEt0MjJKTUM4TEE?oc=5", "source_name": "Market source", "published_at": "2026-02-14T08:00:00+00:00", "published_display": "14 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences (TYRA) Stock Forecast and Price Target 2026 $TYRA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1mbGwwSWUwdXIxSTRZLVFXSnhaS3lsMDVFUjRSWEpZODl5ZDBtRTJJSzE0Q2FUUkJSa0tIeHRoZUlrRXFKRUZmbHE1UmNGWk9Mbk1pTzlfZUVZbFViX1dCN05kRjRHdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:41:20+00:00", "published_display": "11 May 2024 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNVmJiYVVERjVFcktQdTlyMURicjJRbGdUbWYzYTBGZmJsTkhYWjUzdmg5ZE9ESUFTazVaNW0tcTB1eG9jalNnaHNQRy1xWWI4OThQVlZ1eWV2QjBoMEljdFl6ZnVKV2ZwZTFuYnVOVW85d2FJTkl1N2tSSlhBTm0wdFdCcGw5T1gwbFo2UkV6dGhGTU1ZNEFHcHFHR204RkhnRThoY1l1Mkt1WXJvX1c5VktMa2lpbVZ4cWRWMUJJb05VNVYz?oc=5", "source_name": "PR Newswire", "published_at": "2024-02-02T08:00:00+00:00", "published_display": "02 Feb 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tyra Biosciences (TYRA) Stock Price, News & Analysis $TYRA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9ZMTd6OEFxbXBTb2hBcEN6b3BwOFlQN0lzX3dlczgydDZreVRFVjhJTkdFWUFKWWNfNS1ka0VieFNFOTgzWDZvVnJaQWdIMmxPTkxNdXpsb3dKdw?oc=5", "source_name": "MarketBeat", "published_at": "2021-09-17T02:41:54+00:00", "published_display": "17 Sep 2021 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TYRA Stock Price and Chart \u2014 NASDAQ:TYRA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1IWE5kRjBXaldKc0paMWdaSHJuQ0NVaW93MXM5SDAtdDJRNnFWSTRmckpiY2V4NXpOVHU0cVNJUmQ3c3g3b2IwNGNHZnR5SHhrTVVpM01SVHAxbFlF?oc=5", "source_name": "TradingView", "published_at": "2021-09-14T06:44:46+00:00", "published_display": "14 Sep 2021 06:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 58, "sentiment_summary": {"positive": 19, "negative": 7, "neutral": 32, "score": 55, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 17.05, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 5.5, "count": 10}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 32.75, "latest_week": "2026-07-10", "one_week_move": 7.0, "four_week_move": 21.3, "twelve_week_move": -7.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.05425, "market_dynamics_buy_signal": false, "relative_strength": 15.595074, "fair_value_gap": 78.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 48.3172, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.0% over one week, +21.3% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "TradingView", "count": 8}, {"label": "TradingKey", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "PR Newswire", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "www.marketscreener.com", "count": 3}, {"label": "Stock Titan", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 10}, {"label": "Guidance", "count": 3}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.0% over one week, +21.3% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to earnings forward of Tyra Biosciences, Inc. \u2013 NASDAQ:TYRA"}], "updated_at": "2026-07-16T03:30:47.668351+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}